stockrowMerck & Co., Inc.
MRK Healthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.
- Revenue
- +4.68%
- EPS
- −130.7%
- Free cash flow
- +77.0%
- Total debt
- +50.4%
Quarter to September 2026, against a year earlier
Follow MRK
Alert me
Merck & Co., Inc. (MRK) Revenue growth
Merck & Co., Inc.'s revenue growth over the twelve months to 30 September 2026 was 4.89%, up 3.6 percentage points from fiscal 2025 (1.31%). Over the past ten years it has ranged from −7.50% (fiscal 2019) to 21.7% (fiscal 2022); the current reading is higher than 45% of that period. That is below the Drug Manufacturers General industry median of 6.72% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 1.31% | (5.43) |
| FY2024 | 6.74% | 5.34 |
| FY2023 | 1.40% | (20.32) |
| FY2022 | 21.7% | 4.41 |
| FY2021 | 17.3% | 11.18 |
| FY2020 | 6.13% | 13.63 |
| FY2019 | −7.50% | (12.91) |
| FY2018 | 5.41% | 4.62 |
| FY2017 | 0.79% | 0.01 |
| FY2016 | 0.78% | 7.26 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 4.68% | (0.39) |
| Jun 2026 | 5.07% | 0.20 |
| Mar 2026 | 4.87% | (0.10) |
| Dec 2025 | 4.97% | 1.25 |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| NVO Novo Nordisk A/S compare | 13.2% |
| ABBV AbbVie Inc. compare | 10.7% |
| AMGN Amgen Inc. compare | 8.15% |
| JNJ Johnson & Johnson compare | 7.80% |
| AZN AstraZeneca PLC compare | 7.32% |
| GILD Gilead Sciences, Inc. compare | 6.54% |
| MRK Merck & Co., Inc. | 4.89% |
| NVS Novartis AG compare | 1.76% |
| PFE Pfizer Inc. compare | 1.34% |
| Drug Manufacturers General industry median | 6.72% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on MRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement